Acalabrutinib

BRAND NAMES 

Calquence: Calquence is a prescription medication approved by the U.S. Food and Drug Administration for treating certain blood cancers in adults, including Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma. Acalabrutinib, the active ingredient in Calquence, may be used alone or in combination with other cancer treatments depending on the condition and patient needs.

MECHANISM OF ACTION:

Acalabrutinib selectively inhibits Bruton’s tyrosine kinase (BTK), a key enzyme in the B-cell receptor (BCR) signaling pathway. BTK plays an essential role in the growth, survival, and proliferation of malignant B-cells. Acalabrutinib forms a covalent bond with the BTK enzyme, blocking its activity. This inhibition disrupts downstream signaling pathways that normally promote B-cell activation and survival. As a result, the drug reduces the proliferation and induces apoptosis (cell death) of cancerous B-cells. This mechanism is particularly important in diseases such as Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma, where abnormal B-cell signaling drives disease progression.

PHARMACOKINETICS:

Absorption:

Acalabrutinib is rapidly absorbed after oral administration, with moderate to high bioavailability. It can be taken with or without food; however, its absorption may be affected by medications that alter stomach acidity (such as proton pump inhibitors). The drug typically reaches its peak concentration in the bloodstream within approximately 0.5 to 1 hour after dosing.

Distribution:

Acalabrutinib distributes widely in body tissues and is highly protein-bound (97–99%). It is mainly metabolized by liver CYP3A enzymes, with most of the drug excreted in feces and a smaller amount in urine. Its elimination half-life is 1–2 hours, but its active metabolite extends its pharmacologic effect.

Metabolism:

Acalabrutinib is primarily metabolized in the liver, mainly by the CYP3A enzyme system. It undergoes extensive biotransformation to produce an active metabolite (ACP-5862), which also contributes to its pharmacological activity. Only a very small fraction of acalabrutinib is excreted unchanged, indicating that metabolism is the major route of clearance.

Elimination:

Acalabrutinib is primarily eliminated through hepatic metabolism, mainly via the CYP3A enzyme system, producing metabolites that are excreted in feces and to a lesser extent in urine. The kidneys play a minimal role in clearing the unchanged drug, as most of the pharmacologic activity is due to its metabolites. 

PHARMACODYNAMICS

Acalabrutinib is a selective Bruton’s tyrosine kinase (BTK) inhibitor that disrupts the B-cell receptor (BCR) signaling pathway, which is essential for the survival, proliferation, and activation of malignant B-cells. By irreversibly binding to BTK, acalabrutinib inhibits downstream signaling, leading to apoptosis (cell death) and reduced proliferation of cancerous B-cells. In preclinical studies, acalabrutinib demonstrated potent inhibition of BTK activity at nanomolar concentrations and showed synergistic effects when combined with other targeted therapies or anti-cancer agents. It is particularly effective in treating Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma.

ADMINISTRATION

Acalabrutinib is administered orally, usually in the form of capsules. It may be taken alone or in combination with other cancer therapies, depending on the patient’s condition and treatment plan. The drug can be taken with or without food, though absorption may be affected by medications that alter stomach acidity. Dosage and frequency are determined by the patient’s disease type, clinical status, and response to treatment. It is important to follow the prescribed schedule consistently to maintain effective BTK inhibition and optimal therapeutic outcomes.

DOSAGE AND STRENGTH

For adult patients with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Mantle Cell Lymphoma, the recommended dose of Acalabrutinib (marketed as Calquence) is 100 mg taken orally twice daily.

• The capsules should be swallowed whole and can be taken with or without food.

• Dose adjustments may be needed in patients with severe liver impairment or when co-administered with strong CYP3A inhibitors or inducers.

• Pediatric dosing is not widely established; use in children should be under specialist supervision in clinical trials or approved protocols.

• This dosing regimen provides continuous BTK inhibition, optimizing efficacy while minimizing adverse effects.

• If you want, I can make a table version showing standard adult dosing, adjustments, and special situations for easier reference.

DRUG INTERACTIONS

Acalabrutinib is mainly metabolized by CYP3A, so drugs that strongly affect this enzyme can change its effectiveness or increase toxicity. Caution is needed with anticoagulants or antiplatelet agents, and patients with prior hypersensitivity or serious bleeding history should be carefully evaluated.

FOOD INTERACTIONS

Acalabrutinib can be taken with or without food, as absorption is not significantly affected. Medications that alter stomach acidity may impact its effectiveness, and patients should follow their doctor’s advice regarding alcohol use.

CONTRAINDICATIONS

Acalabrutinib is contraindicated in patients allergic to it or its components. It should also be avoided in severe liver impairment due to increased toxicity risk.

SIDE EFFECTS

• Fatigue or feeling unusually tired

• Headache

• Diarrhea or nausea

• Bruising or minor bleeding

• Muscle or joint pain

• In some patients: fever, chills, or general malaise

TOXICITY

Acalabrutinib (Calquence) can cause serious toxicities such as bleeding, infections, and heart rhythm problems. Other side effects include low blood counts, elevated liver enzymes, headache, and diarrhea. Patients need careful monitoring to manage these risks.